RT Journal
A1 Hay JW
T1 What is more valuable: Fenofibrate patents or fenofibrate clinical outcomes?
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD October 22
VO 172
IS 19
SP 1521
OP 1522
DO 10.1001/archinternmed.2012.4386
UL http://dx.doi.org/10.1001/archinternmed.2012.4386
AB 
Downing et al1 present the opinion that Abbott's various brands of fenofibrate and fenofibric acid inappropriately manipulated the patent and drug approval process to protect brand profits. However, it is likely that Abbott would have provided substantial confidential rebates and discounts for its various branded fenofibrate products to maintain favorable formulary status and market share. Absent this and other confidential trial document information, it is impossible to know if and how much consumers were actually harmed by Abbott's alleged behavior.